AstraZeneca-Ionis Heart Drug Fails; Alnylam Watches
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca and Ionis detailed a surprise failure of their experimental heart disease drug in results presented at the European Society of Cardiology meeting
- AstraZeneca used the post-mortem of the failed trial to raise broader questions about the viability of "silencer drugs" — a drug class that targets disease at the RNA level — for cardiovascular indications
- Alnylam, a leading developer of RNA-silencing therapeutics, is closely watching the outcome as a competitor with overlapping pipeline interests
- The failure is a surprise given the drug's prior development trajectory, and its read-through extends beyond AstraZeneca and Ionis to the entire RNA-interference approach in cardiology
Why it matters: A high-profile trial loss in a closely watched cardiovascular indication casts doubt on the broader RNA-silencer drug class, directly pressuring Alnylam's competing pipeline and any developer betting on similar mechanisms in heart disease.
Ask SkimNews
